US Stock MarketDetailed Quotes

CYTK Cytokinetics

Watchlist
  • 47.670
  • -2.190-4.39%
Close Nov 21 16:00 ET
  • 47.810
  • +0.140+0.29%
Post 16:05 ET
5.63BMarket Cap-8860P/E (TTM)

About Cytokinetics Company

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Company Profile

SymbolCYTK
Company NameCytokinetics
Listing DateApr 29, 2004
Issue Price13.00
Founded1997
CEOMr. Robert I. Blum
MarketNASDAQ
Employees564
Fiscal Year Ends12-31
Address350 Oyster Point Boulevard
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-650-624-3000

Company Executives

  • Name
  • Position
  • Salary
  • Robert I. Blum
  • Director, President and Chief Executive Officer
  • 8.75M
  • Sung H. Lee
  • Executive Vice President and Chief Financial Officer
  • --
  • Brett A. Pletcher
  • Executive Vice President and Chief Legal Officer
  • --
  • Andrew M. Callos
  • Executive Vice President and Chief Commercial Officer
  • 3.20M
  • Robert C. Wong
  • Vice President and Chief Accounting Officer
  • 1.04M
  • Dr. Fady Ibraham Malik, M.D.,PhD
  • Executive Vice President, Research and Development
  • 4.44M
  • Dr. John T. Henderson, M.B.
  • Chairman of the Board
  • 559.02K
  • Muna Bhanji, Ph.
  • Independent Director
  • 509.02K
  • B. Lynne Parshall, Esq.,J.D.
  • Independent Director
  • 529.02K
  • Dr. Wendell D. Wierenga,PhD
  • Independent Director
  • 529.02K
  • Dr. Edward M. Kaye, M.D.
  • Independent Director
  • 514.02K
  • Nancy J. Wysenski
  • Independent Director
  • 519.02K
  • Dr. Robert A. Harrington, M.D.
  • Independent Director
  • 504.02K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data